Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001967168Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationImage: Contact Information

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Kintz Samuel

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market		Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave, 4th Fl New York NY 10022	12000	336120.00	47000000	10/09/2024	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is Date this Donor a Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
-----------------------	----------------------	---	--	-------------------------------------	-------------------------------------	--------------------	------------------------

Common	06/12/2019 Founder Shares	Enliven	12000	06/12/2019
		Therapeutics		

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

9 N/A

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Samuel Kintz 6200 Lookout Road, 1st Fl Boulder CO 80301	Enliven Therapeutics	08/26/2024	12000	274718.04
Samuel Kintz 6200 Lookout Road, 1st Fl Boulder CO 80301	Enliven Therapeutics	10/01/2024 5	526	14484.54
Samuel Kintz 6200 Lookout Road, 1st Fl Boulder CO 80301	Enliven Therapeutics	10/04/2024	12206	335792.55
Samuel Kintz 6200 Lookout Road, 1st Fl Boulder CO 80301	Enliven Therapeutics	10/07/2024 2	2730	75075.00
Samuel Kintz 6200 Lookout Road, 1st Fl Boulder CO 80301	Enliven Therapeutics	10/08/2024	13267	370929.53
Samuel Kintz 6200 Lookout Road, 1st Fl Boulder CO 80301	Enliven Therapeutics	10/09/2024 4	4710	132591.69

144: Remarks and Signature

RemarksAll Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated
06/26/2023, and all representations regarding material non-public information were made as of the
adoption of the plan. The shares in this filing will be sold from THE KINTZ & EGAN TRUST UAD
03/30/19.Date of Notice10/09/2024Date of Plan Adoption
or Giving of Instruction,
If Relying on Rule 10b5-06/26/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Sam Kintz

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)